TLR3 and neoplasm: Although we have not performed genetic validation such as pathway blocks or gene knockout studies, our evidence suggests a number of important potential cancer therapy leads including the TLR3 and TLR4, expressed by tumor cells, may activate cytokine pathways that lead to immune cell recruitment and an inflammatory response via the MyD88 pathway.